
## Jessica Zucman-Rossi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5118071/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Signatures of mutational processes in human cancer. Nature, 2013, 500, 415-421.	13.7	8,060
2	Hepatocellular carcinoma. Nature Reviews Disease Primers, 2021, 7, 6.	18.1	2,757
3	International network of cancer genome projects. Nature, 2010, 464, 993-998.	13.7	2,114
4	Hepatocellular carcinoma. Nature Reviews Disease Primers, 2016, 2, 16018.	18.1	1,863
5	Gene fusion with an ETS DNA-binding domain caused by chromosome translocation in human tumours. Nature, 1992, 359, 162-165.	13.7	1,724
6	Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nature Genetics, 2015, 47, 505-511.	9.4	1,372
7	Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2. Nature, 1993, 363, 515-521.	13.7	1,351
8	Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nature Genetics, 2012, 44, 694-698.	9.4	1,229
9	Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology, 2007, 45, 42-52.	3.6	1,034
10	The Ewing Family of Tumors A Subgroup of Small-Round-Cell Tumors Defined by Specific Chimeric Transcripts. New England Journal of Medicine, 1994, 331, 294-299.	13.9	1,010
11	Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. Gastroenterology, 2015, 149, 1226-1239.e4.	0.6	980
12	Genotype–phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC. Hepatology, 2006, 43, 515-524.	3.6	733
13	Mechanisms of HBV-induced hepatocellular carcinoma. Journal of Hepatology, 2016, 64, S84-S101.	1.8	664
14	MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology, 2008, 47, 1955-1963.	3.6	634
15	Toward understanding and exploiting tumor heterogeneity. Nature Medicine, 2015, 21, 846-853.	15.2	604
16	Hepatocellular adenoma subtype classification using molecular markers and immunohistochemistry. Hepatology, 2007, 46, 740-748.	3.6	554
17	Ewing sarcoma 11;22 translocation produces a chimeric transcription factor that requires the DNA-binding domain encoded by FLI1 for transformation Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 5752-5756.	3.3	538
18	A gp130–Src–YAP module links inflammation to epithelial regeneration. Nature, 2015, 519, 57-62.	13.7	528

2

#	Article	IF	CITATIONS
19	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. Journal of Hepatology, 2017, 67, 727-738.	1.8	525
20	High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nature Communications, 2013, 4, 2218.	5.8	513
21	EWS and ATF-1 gene fusion induced by t(12;22) translocation in malignant melanoma of soft parts. Nature Genetics, 1993, 4, 341-345.	9.4	483
22	Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature, 2009, 457, 200-204.	13.7	437
23	Hepatocellular adenoma management and phenotypic classification: The Bordeaux experience. Hepatology, 2009, 50, 481-489.	3.6	394
24	Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nature Genetics, 2015, 47, 1187-1193.	9.4	387
25	EASL Clinical Practice Guidelines on the management of benign liver tumours. Journal of Hepatology, 2016, 65, 386-398.	1.8	372
26	DNA methylationâ€based prognosis and epidrivers in hepatocellular carcinoma. Hepatology, 2015, 61, 1945-1956.	3.6	367
27	GNAS-activating mutations define a rare subgroup of inflammatory liver tumors characterized by STAT3 activation. Journal of Hepatology, 2012, 56, 184-191.	1.8	354
28	Genomic portrait of resectable hepatocellular carcinomas: Implications of <i>RB1</i> and <i>FGF19</i> aberrations for patient stratification. Hepatology, 2014, 60, 1972-1982.	3.6	345
29	Bi-allelic inactivation of TCF1 in hepatic adenomas. Nature Genetics, 2002, 32, 312-315.	9.4	333
30	Molecular and histological correlations in liver cancer. Journal of Hepatology, 2019, 71, 616-630.	1.8	308
31	Genetics of hepatocellular tumors. Oncogene, 2006, 25, 3778-3786.	2.6	304
32	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. Gastroenterology, 2013, 145, 176-187.	0.6	302
33	Molecular Classification of Hepatocellular Adenoma AssociatesÂWith Risk Factors, Bleeding, and Malignant Transformation. Gastroenterology, 2017, 152, 880-894.e6.	0.6	290
34	Cloning and characterization of the Ewing's sarcoma and peripheral neuroepithelioma t(11;22) translocation breakpoints. Genes Chromosomes and Cancer, 1992, 5, 271-277.	1.5	284
35	Hepatocellular adenomas: Magnetic resonance imaging features as a function of molecular pathological classification. Hepatology, 2008, 48, 808-818.	3.6	277
36	Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology, 2014, 60, 1983-1992.	3.6	268

#	Article	IF	CITATIONS
37	Hepatocellular Benign Tumors—From Molecular Classification to Personalized Clinical Care. Gastroenterology, 2013, 144, 888-902.	0.6	251
38	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated with Sunitinib Response in the Metastatic Setting. Clinical Cancer Research, 2015, 21, 1329-1339.	3.2	250
39	cHCC CA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology, 2018, 68, 113-126.	3.6	244
40	Genomic Profiling of Hepatocellular Adenomas Reveals Recurrent FRK-Activating Mutations and the Mechanisms of Malignant Transformation. Cancer Cell, 2014, 25, 428-441.	7.7	240
41	Molecular pathogenesis of focal nodular hyperplasia and hepatocellular adenoma. Journal of Hepatology, 2008, 48, 163-170.	1.8	235
42	Differential effects of inactivated Axin1 and activated β-catenin mutations in human hepatocellular carcinomas. Oncogene, 2007, 26, 774-780.	2.6	230
43	Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis. Nature Communications, 2017, 8, 1315.	5.8	228
44	Genotypeâ€phenotype correlation of CTNNB1 mutations reveals different ßâ€catenin activity associated with liver tumor progression. Hepatology, 2016, 64, 2047-2061.	3.6	222
45	Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma. Journal of Hepatology, 2019, 70, 58-65.	1.8	219
46	Somatic mutations activating STAT3 in human inflammatory hepatocellular adenomas. Journal of Experimental Medicine, 2011, 208, 1359-1366.	4.2	218
47	High Incidence of Activating <scp><i>TERT</i></scp> Promoter Mutations in Meningiomas Undergoing Malignant Progression. Brain Pathology, 2014, 24, 184-189.	2.1	209
48	Clinical, Morphologic, and Molecular Features Defining So-Called Telangiectatic Focal Nodular Hyperplasias of the Liver. Gastroenterology, 2005, 128, 1211-1218.	0.6	207
49	A MYC–aurora kinase A protein complex represents an actionable drug target in p53-altered liver cancer. Nature Medicine, 2016, 22, 744-753.	15.2	207
50	PNPLA3 gene in liver diseases. Journal of Hepatology, 2016, 65, 399-412.	1.8	205
51	Oncogenic conversion of a novel orphan nuclear receptor by chromosome translocation. Human Molecular Genetics, 1995, 4, 2219-2226.	1.4	190
52	Tissue metabolomics of hepatocellular carcinoma: Tumor energy metabolism and the role of transcriptomic classification. Hepatology, 2013, 58, 229-238.	3.6	172
53	Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. Journal of Hepatology, 2007, 46, 521-527.	1.8	170
54	Familia liver adenomatosis associated with hepatocyte nuclear factor 11± inactivation1 1The authors thank Leigh Pascoe for critical reading of the manuscript, HélÃ"ne Blanché and Hung Bui of the CEPH/Fondation Jean Dausset for technical help in sequencing, and Drs. A. Saillant, E. Akodjenou, and E. Urvoas (Pediatric and Radiology Units, HÃ'pitaux de Chartres, France) for referring patient B1 to E.J. and for performing liver ultrasound screening in family B Gastroenterology, 2003, 125, 1470-1475.	0.6	169

#	Article	IF	CITATIONS
55	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. Advances in Immunology, 2016, 130, 95-190.	1.1	160
56	Macrotrabecularâ€massive hepatocellular carcinoma: A distinctive histological subtype with clinical relevance. Hepatology, 2018, 68, 103-112.	3.6	159
57	The role of telomeres and telomerase in cirrhosis and liver cancer. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 544-558.	8.2	154
58	Liver Cancer Initiation Requires p53 Inhibition by CD44-Enhanced Growth Factor Signaling. Cancer Cell, 2018, 33, 1061-1077.e6.	7.7	151
59	Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. Oncogene, 1999, 18, 4044-4046.	2.6	149
60	High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH. Human Molecular Genetics, 2001, 10, 271-282.	1.4	147
61	Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. Journal of Hepatology, 2013, 58, 350-357.	1.8	146
62	Loss of Trim24 (Tif1α) gene function confers oncogenic activity to retinoic acid receptor alpha. Nature Genetics, 2007, 39, 1500-1506.	9.4	145
63	Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. Gastroenterology, 2019, 156, 492-509.	0.6	145
64	Overâ€expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver International, 2009, 29, 459-465.	1.9	143
65	Subtype Classification of Hepatocellular Adenoma. Digestive Surgery, 2010, 27, 39-45.	0.6	143
66	Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response. Gastroenterology, 2019, 157, 760-776.	0.6	141
67	Single nucleotide polymorphisms and risk of hepatocellular carcinoma in cirrhosis. Journal of Hepatology, 2012, 57, 663-674.	1.8	140
68	Genetics of Hepatobiliary Carcinogenesis. Seminars in Liver Disease, 2011, 31, 173-187.	1.8	138
69	Mutational signature analysis identifies <i><scp>MUTYH</scp></i> deficiency in colorectal cancers and adrenocortical carcinomas. Journal of Pathology, 2017, 242, 10-15.	2.1	130
70	Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma. Hepatology, 2020, 71, 164-182.	3.6	129
71	Integration of tumour and viral genomic characterisations in HBV-related hepatocellular carcinomas. Gut, 2015, 64, 820-829.	6.1	127
72	Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. Journal of Hepatology, 2004, 41, 292-298.	1.8	126

#	Article	IF	CITATIONS
73	HOX11L2 expression defines a clinical subtype of pediatric T-ALL associated with poor prognosis. Blood, 2002, 100, 991-997.	0.6	125
74	Dissecting heterogeneity in malignant pleural mesothelioma through histo-molecular gradients for clinical applications. Nature Communications, 2019, 10, 1333.	5.8	125
75	Hepatocyte Nuclear Factor-1α Gene Inactivation: Cosegregation between Liver Adenomatosis and Diabetes Phenotypes in Two Maturity-Onset Diabetes of the Young (MODY)3 Families. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 1476-1480.	1.8	124
76	HNF1α Inactivation Promotes Lipogenesis in Human Hepatocellular Adenoma Independently of SREBP-1 and Carbohydrate-response Element-binding Protein (ChREBP) Activation. Journal of Biological Chemistry, 2007, 282, 14437-14446.	1.6	123
77	Molecular Classification of Malignant Pleural Mesothelioma: Identification of a Poor Prognosis Subgroup Linked to the Epithelial-to-Mesenchymal Transition. Clinical Cancer Research, 2014, 20, 1323-1334.	3.2	121
78	Molecular classification of hepatocellular adenoma in clinical practice. Journal of Hepatology, 2017, 67, 1074-1083.	1.8	119
79	Immunohistochemical Markers on Needle Biopsies Are Helpful for the Diagnosis of Focal Nodular Hyperplasia and Hepatocellular Adenoma Subtypes. American Journal of Surgical Pathology, 2012, 36, 1691-1699.	2.1	118
80	Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress. Nature Communications, 2018, 9, 5235.	5.8	118
81	Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Annals of Oncology, 2011, 22, 794-800.	0.6	116
82	RIPK1 Suppresses a TRAF2-Dependent Pathway to Liver Cancer. Cancer Cell, 2017, 31, 94-109.	7.7	115
83	Revisiting the Pathology of Resected Benign Hepatocellular Nodules Using New Immunohistochemical Markers. Seminars in Liver Disease, 2011, 31, 091-103.	1.8	112
84	Germline hepatocyte nuclear factor 1α and 1β mutations in renal cell carcinomas. Human Molecular Genetics, 2005, 14, 603-614.	1.4	109
85	Unique Genomic Profile of Fibrolamellar Hepatocellular Carcinoma. Gastroenterology, 2015, 148, 806-818.e10.	0.6	109
86	Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma. Gut, 2022, 71, 616-626.	6.1	106
87	Genomic Profiling Reveals Alternative Genetic Pathways of Meningioma Malignant Progression Dependent on the Underlying <i>NF2</i> Status. Clinical Cancer Research, 2010, 16, 4155-4164.	3.2	103
88	Trial Watch: Monoclonal antibodies in cancer therapy. Oncolmmunology, 2012, 1, 28-37.	2.1	103
89	Chromosome translocation based on illegitimate recombination in human tumors. Proceedings of the National Academy of Sciences of the United States of America, 1998, 95, 11786-11791.	3.3	101
90	Overexpression and role of the ATPase and putative DNA helicase RuvB-like 2 in human hepatocellular carcinoma. Hepatology, 2007, 46, 1108-1118.	3.6	100

#	Article	IF	CITATIONS
91	Inactivation of the <i>APC</i> Gene Is Constant in Adrenocortical Tumors from Patients with Familial Adenomatous Polyposis but Not Frequent in Sporadic Adrenocortical Cancers. Clinical Cancer Research, 2010, 16, 5133-5141.	3.2	97
92	Genomic structure of the EWS gene and its relationship to EWSR1, a site of tumor-associated chromosome translocation. Genomics, 1993, 18, 609-615.	1.3	94
93	Modeling a human hepatocellular carcinoma subset in mice through coexpression of met and pointâ€mutant βâ€catenin. Hepatology, 2016, 64, 1587-1605.	3.6	92
94	Inhibiting Glutamine-Dependent mTORC1 Activation Ameliorates Liver Cancers Driven by β-Catenin Mutations. Cell Metabolism, 2019, 29, 1135-1150.e6.	7.2	92
95	Genotype phenotype classification of hepatocellular adenoma. World Journal of Gastroenterology, 2007, 13, 2649.	1.4	90
96	Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib. British Journal of Cancer, 2013, 108, 887-900.	2.9	88
97	The β-catenin pathway is activated in focal nodular hyperplasia but not in cirrhotic FNH-like nodules. Journal of Hepatology, 2008, 49, 61-71.	1.8	87
98	microRNA 193a-5p Regulates Levels of Nucleolar- and Spindle-Associated Protein 1 to Suppress Hepatocarcinogenesis. Gastroenterology, 2018, 155, 1951-1966.e26.	0.6	86
99	Polyploidy spectrum: a new marker in HCC classification. Gut, 2020, 69, 355-364.	6.1	82
100	Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort Study. Gastroenterology, 2018, 155, 431-442.e10.	0.6	81
101	Dual Targeting of Histone Methyltransferase G9a and DNAâ€Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. Hepatology, 2019, 69, 587-603.	3.6	81
102	Hepatocellular adenoma: what is new in 2008. Hepatology International, 2008, 2, 316-321.	1.9	78
103	TERT promoter mutations in primary liver tumors. Clinics and Research in Hepatology and Gastroenterology, 2016, 40, 9-14.	0.7	78
104	AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation. Journal of Hepatology, 2018, 68, 1203-1213.	1.8	78
105	Adeno-associated virus in the liver: natural history and consequences in tumour development. Gut, 2020, 69, 737-747.	6.1	78
106	KIF20A mRNA and Its Product MKlp2 Are Increased During Hepatocyte Proliferation and Hepatocarcinogenesis. American Journal of Pathology, 2012, 180, 131-140.	1.9	76
107	A functional screening identifies five micrornas controlling glypican-3: role of mir-1271 down-regulation in hepatocellular carcinoma. Hepatology, 2013, 57, 195-204.	3.6	76
108	Identification of Novel Oncogenes and Tumor Suppressors in Hepatocellular Carcinoma. Seminars in Liver Disease, 2010, 30, 075-086.	1.8	75

#	Article	IF	CITATIONS
109	A 17â€Betaâ€Hydroxysteroid Dehydrogenase 13 Variant Protects From Hepatocellular Carcinoma Development in Alcoholic Liver Disease. Hepatology, 2019, 70, 231-240.	3.6	75
110	From the Editor's desk Journal of Hepatology, 2018, 69, 1-4.	1.8	74
111	Genetic alterations of malignant pleural mesothelioma: associationÂwith tumor heterogeneity and overall survival. Molecular Oncology, 2020, 14, 1207-1223.	2.1	74
112	Molecular classification of hepatocellular carcinoma. Digestive and Liver Disease, 2010, 42, S235-S241.	0.4	73
113	Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy. European Urology, 2018, 74, 474-480.	0.9	72
114	PNPLA3 and TM6SF2 variants as risk factors of hepatocellular carcinoma across various etiologies and severity of underlying liver diseases. International Journal of Cancer, 2019, 144, 533-544.	2.3	72
115	Recurrent inactivating mutations of <i>ARID2</i> in nonâ€small cell lung carcinoma. International Journal of Cancer, 2013, 132, 2217-2221.	2.3	70
116	Cloning of a balanced translocation breakpoint in the DiGeorge syndrome critical region and isolation of a novel potential adhesion receptor gene in its vicinity. Human Molecular Genetics, 1995, 4, 551-558.	1.4	69
117	NF2 gene in neurofibromatosis type 2 patients. Human Molecular Genetics, 1998, 7, 2095-2101.	1.4	69
118	CXCR7 is up-regulated in human and murine hepatocellular carcinoma and is specifically expressed by endothelial cells. European Journal of Cancer, 2012, 48, 138-148.	1.3	68
119	Prognostic impact of baseline serum <scp>C</scp> â€reactive protein in patients with metastatic renal cell carcinoma ( <scp>RCC</scp> ) treated with sunitinib. BJU International, 2014, 114, 81-89.	1.3	68
120	Overexpression and promoter mutation of the TERT gene in malignant pleural mesothelioma. Oncogene, 2014, 33, 3748-3752.	2.6	68
121	Interphase molecular cytogenetics of Ewing's sarcoma and peripheral neuroepithelioma t(11;22) with flanking and overlapping cosmid probes. Cancer Genetics and Cytogenetics, 1994, 74, 13-18.	1.0	67
122	Co-occurring Mutations of Tumor Suppressor Genes, <i>LATS2</i> and <i>NF2</i> , in Malignant Pleural Mesothelioma. Clinical Cancer Research, 2017, 23, 3191-3202.	3.2	67
123	Loss of hepatocyte nuclear factor 11± function in human hepatocellular adenomas leads to aberrant activation of signaling pathways involved in tumorigenesis. Hepatology, 2010, 51, 557-566.	3.6	66
124	A Novel Epigenetic Phenotype Associated With the Most Aggressive Pathway of Bladder Tumor Progression. Journal of the National Cancer Institute, 2011, 103, 47-60.	3.0	66
125	Genetics of Hepatocellular Carcinoma: Approaches to Explore Molecular Diversity. Hepatology, 2021, 73, 14-26.	3.6	66
126	Nivolumab, nivolumab–ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 612-624.	5.1	66

#	Article	IF	CITATIONS
127	Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. Oncogene, 2002, 21, 1225-1232.	2.6	65
128	ESM1 as a Marker of Macrotrabecular-Massive Hepatocellular Carcinoma. Clinical Cancer Research, 2019, 25, 5859-5865.	3.2	64
129	Association of CYP1B1 Germ Line Mutations with Hepatocyte Nuclear Factor 1α–Mutated Hepatocellular Adenoma. Cancer Research, 2007, 67, 2611-2616.	0.4	62
130	Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. Cancer Research, 2000, 60, 707-11.	0.4	62
131	Mapping of human chromosome 22 with a panel of somatic cell hybrids. Genomics, 1991, 9, 721-727.	1.3	60
132	The <i>HOX</i> gene network in hepatocellular carcinoma. International Journal of Cancer, 2011, 129, 2577-2587.	2.3	60
133	Genetics of hepatocellular carcinoma: The next generation. Journal of Hepatology, 2014, 60, 224-226.	1.8	59
134	Role of Contrast-Enhanced Sonography in Differentiation of Subtypes of Hepatocellular Adenoma: Correlation with MRI Findings. American Journal of Roentgenology, 2012, 199, 341-348.	1.0	58
135	Hepatocyte nuclear factor 1α suppresses steatosis-associated liver cancer by inhibiting PPARγ transcription. Journal of Clinical Investigation, 2017, 127, 1873-1888.	3.9	58
136	Spectrum of <i>HNF1A</i> Somatic Mutations in Hepatocellular Adenoma Differs From That in Patients With MODY3 and Suggests Genotoxic Damage. Diabetes, 2010, 59, 1836-1844.	0.3	57
137	Proliferation Markers Are Associated with MET Expression in Hepatocellular Carcinoma and Predict Tivantinib Sensitivity <i>In Vitro</i> . Clinical Cancer Research, 2017, 23, 4364-4375.	3.2	57
138	Adenosine triphosphatase pontin is overexpressed in hepatocellular carcinoma and coregulated with reptin through a new posttranslational mechanism. Hepatology, 2009, 50, 1871-1883.	3.6	54
139	Telomere length is key to hepatocellular carcinoma diversity and telomerase addiction is an actionable therapeutic target. Journal of Hepatology, 2021, 74, 1155-1166.	1.8	54
140	Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. Journal of Hepatology, 2012, 56, 869-876.	1.8	53
141	Rnd3/RhoE Is down-regulated in hepatocellular carcinoma and controls cellular invasion. Hepatology, 2012, 55, 1766-1775.	3.6	53
142	Palimpsest: an R package for studying mutational and structural variant signatures along clonal evolution in cancer. Bioinformatics, 2018, 34, 3380-3381.	1.8	53
143	Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification. International Journal of Hepatology, 2013, 2013, 1-12.	0.4	52
144	Interethnic polymorphism of EWS intron 6: genome plasticity mediated by Alu retroposition and recombination. Human Genetics, 1997, 99, 357-363.	1.8	51

#	Article	IF	CITATIONS
145	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). Oncolmmunology, 2015, 4, e1049804.	2.1	51
146	Identification of New Members of the Gas2 and Ras Families in the 22q12 Chromosome Region. Genomics, 1996, 38, 247-254.	1.3	50
147	p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. Lung Cancer, 2010, 67, 23-30.	0.9	50
148	STAT3 mutations identified in human hematologic neoplasms induce myeloid malignancies in a mouse bone marrow transplantation model. Haematologica, 2013, 98, 1748-1752.	1.7	50
149	p53 mutations in human tumors with chimericEWS/FLI/1 genes. International Journal of Cancer, 1994, 57, 336-340.	2.3	49
150	Unicolor and bicolor in situ hybridization in the diagnosis of peripheral neuroepithelioma and related tumors. Genes Chromosomes and Cancer, 1992, 5, 30-34.	1.5	48
151	Syntenic Relationships between Genomic Profiles of Fiber-Induced Murine and Human Malignant Mesothelioma. American Journal of Pathology, 2011, 178, 881-894.	1.9	48
152	The liverâ€specific microRNAâ€122*, the complementary strand of microRNAâ€122, acts as a tumor suppressor by modulating the p53/mouse double minute 2 homolog circuitry. Hepatology, 2016, 64, 1623-1636.	3.6	48
153	Molecular Profiling of Liver Tumors: Classification and Clinical Translation for Decision Making. Seminars in Liver Disease, 2014, 34, 363-375.	1.8	47
154	Identification of homozygous deletions at chromosome 16q23 in Aflatoxin B1 exposed hepatocellular carcinoma. Oncogene, 2001, 20, 5232-5238.	2.6	45
155	Similar Tumor Suppressor Gene Alteration Profiles in Asbestos-Induced Murine and Human Mesothelioma. Cell Cycle, 2005, 4, 1862-1869.	1.3	45
156	VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib – a multicentric retrospective analysis. Acta Oncológica, 2014, 53, 103-112.	0.8	45
157	Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis. Modern Pathology, 2016, 29, 43-50.	2.9	45
158	BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA. Journal of Hepatology, 2020, 72, 924-936.	1.8	44
159	Argininosuccinate synthase 1 and periportal gene expression in sonic hedgehog hepatocellular adenomas. Hepatology, 2018, 68, 964-976.	3.6	43
160	The identification of small nodules in liver adenomatosis. Journal of Hepatology, 2003, 39, 77-85.	1.8	42
161	Mutations leading to constitutive active gp130/JAK1/STAT3 pathway. Cytokine and Growth Factor Reviews, 2015, 26, 499-506.	3.2	42
162	TGF-β1 promotes linear invadosome formation in hepatocellular carcinoma cells, through DDR1 up-regulation and collagen I cross-linking. European Journal of Cell Biology, 2016, 95, 503-512.	1.6	41

#	Article	IF	CITATIONS
163	Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma. Acta Oncológica, 2018, 57, 498-508.	0.8	41
164	Integrated Genomic Analysis Identifies Driver Genes and Cisplatin-Resistant Progenitor Phenotype in Pediatric Liver Cancer. Cancer Discovery, 2021, 11, 2524-2543.	7.7	41
165	An adult male patient with multiple adenomas and a hepatocellular carcinoma: Mild Glycogen Storage Disease type Ia. Journal of Hepatology, 2010, 53, 213-217.	1.8	40
166	Biochemical and functional analyses of gp130 mutants unveil JAK1 as a novel therapeutic target in human inflammatory hepatocellular adenoma. OncoImmunology, 2013, 2, e27090.	2.1	39
167	Organization and expression of the λ-like genes that contribute to the μ- Ψ light chain complex in human pre-B cells. International Immunology, 1991, 3, 1081-1090.	1.8	38
168	LINE-I element insertion at the t(11;22) translocation breakpoint of a desmoplastic small round cell tumor. , 1997, 18, 232-239.		38
169	Note of caution: Contaminations of hepatocellular cell lines. Journal of Hepatology, 2017, 67, 896-897.	1.8	37
170	Molecular Subtypes of Clear Cell Renal Cell Carcinoma Are Associated With Outcome During Pazopanib Therapy in the Metastatic Setting. Clinical Genitourinary Cancer, 2018, 16, e605-e612.	0.9	37
171	Expression of NKG2D ligands is downregulated by β-catenin signalling and associates with HCC aggressiveness. Journal of Hepatology, 2021, 74, 1386-1397.	1.8	37
172	Mapping of Human Î <sup>3</sup> -Glutamyl Transpeptidase Genes on Chromosome 22 and Other Human Autosomes. Genomics, 1993, 17, 299-305.	1.3	36
173	Absence of mutation in the putative tumor-suppressor gene KLF6 in colorectal cancers. Oncogene, 2005, 24, 7253-7256.	2.6	36
174	Lect2 Controls Inflammatory Monocytes to Constrain the Growth and Progression of Hepatocellular Carcinoma. Hepatology, 2019, 69, 160-178.	3.6	36
175	Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. Lancet Oncology, The, 2022, 23, 161-171.	5.1	36
176	HNF1α inhibition triggers epithelial-mesenchymal transition in human liver cancer cell lines. BMC Cancer, 2011, 11, 427.	1.1	35
177	Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. Mutagenesis, 2013, 28, 323-331.	1.0	35
178	Regressive liver adenomatosis following androgenic progestin therapy withdrawal: a case report with a 10-year follow-up and a molecular analysis. European Journal of Endocrinology, 2007, 156, 617-621.	1.9	34
179	Multidisciplinary strategies to improve treatment outcomes in hepatocellular carcinoma. European Journal of Gastroenterology and Hepatology, 2013, 25, 639-651.	0.8	34
180	Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors. Clinical Genitourinary Cancer, 2019, 17, e981-e994.	0.9	34

#	Article	IF	CITATIONS
181	Genetic alterations in hepatocellular adenomas: recent findings and new challenges. Journal of Hepatology, 2004, 40, 1036-1039.	1.8	33
182	Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. Pharmacogenomics, 2007, 8, 997-1003.	0.6	33
183	Wild-type AAV Insertions in Hepatocellular Carcinoma Do Not Inform Debate Over Genotoxicity Risk of Vectorized AAV. Molecular Therapy, 2016, 24, 660-661.	3.7	33
184	Assignment of the human stromelysin 3 (STMY3) gene to the q11.2 region of chromosome 22. Genomics, 1992, 13, 881-883.	1.3	32
185	Mutation of TP53 gene is involved in carcinogenesis of hepatic undifferentiated (embryonal) sarcoma of the adult, in contrast with Wnt or telomerase pathways: an immunohistochemical study of three cases with genomic relation in two cases. Journal of Hepatology, 2005, 42, 424-429.	1.8	32
186	Keratin 23 is a stress-inducible marker of mouse and human ductular reaction in liver disease. Journal of Hepatology, 2016, 65, 552-559.	1.8	32
187	Natural history of liver adenomatosis: A long-term observational study. Journal of Hepatology, 2019, 71, 1184-1192.	1.8	32
188	Absence of KLF6 gene mutation in 71 hepatocellular carcinomas. Hepatology, 2005, 41, 681-682.	3.6	31
189	Germline and somatic DICER1 mutations in familial and sporadic liver tumors. Journal of Hepatology, 2017, 66, 734-742.	1.8	31
190	Dietary exacerbation of metabolic stress leads to accelerated hepatic carcinogenesis in glycogen storage disease type Ia. Journal of Hepatology, 2018, 69, 1074-1087.	1.8	31
191	<i>APC</i> germline hepatoblastomas demonstrate cisplatin-induced intratumor tertiary lymphoid structures. Oncolmmunology, 2019, 8, e1583547.	2.1	31
192	Multi-site tumor sampling highlights molecular intra-tumor heterogeneity in malignant pleural mesothelioma. Genome Medicine, 2021, 13, 113.	3.6	31
193	Efflux pump ABCB1 single nucleotide polymorphisms and dose reductions in patients with metastatic renal cell carcinoma treated with sunitinib. Acta Oncológica, 2014, 53, 1413-1422.	0.8	30
194	Long Noncoding RNA NIHCOLE Promotes Ligation Efficiency of DNA Double-Strand Breaks in Hepatocellular Carcinoma. Cancer Research, 2021, 81, 4910-4925.	0.4	30
195	Gene expression signature as a surrogate marker of microvascular invasion on routine hepatocellular carcinoma biopsies. Journal of Hepatology, 2022, 76, 343-352.	1.8	30
196	Focal nodular hyperplasia, hepatocellular adenomas: Past, present, future. Gastroenterologie Clinique Et Biologique, 2010, 34, 355-358.	0.9	29
197	Dinucleotide repeat polymorphism at the D22S268 locus. Human Molecular Genetics, 1993, 2, 336-336.	1.4	28
198	Hepatocellular adenoma displaying a HNF11± inactivation in a patient with familial adenomatous polyposis coli. Journal of Hepatology, 2006, 45, 883-886.	1.8	28

#	Article	IF	CITATIONS
199	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. Cancer Discovery, 2021, 11, 408-423.	7.7	28
200	The IncRNA H19-Derived MicroRNA-675 Promotes Liver Necroptosis by Targeting FADD. Cancers, 2021, 13, 411.	1.7	28
201	Characterisation of 16 polymorphic markers in theNF2 gene: Application to hemizygosity detection. Human Mutation, 1999, 13, 290-293.	1.1	27
202	Benign hepatocellular nodules: What have we learned using the patho-molecular classification. Clinics and Research in Hepatology and Gastroenterology, 2013, 37, 322-327.	0.7	26
203	LBA25 Results from the phase II biomarker driven trial with nivolumab (N) and ipilimumab or VEGFR tyrosine kinase inhibitor (TKI) in naÃ־ve metastatic kidney cancer (m-ccRCC) patients (pts): The BIONIKK trial. Annals of Oncology, 2020, 31, S1157.	0.6	26
204	ALDH3A1 is overexpressed in a subset of hepatocellular carcinoma characterised by activation of the Wnt/ÄŸ-catenin pathway. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2014, 464, 53-60.	1.4	25
205	Next-generationsequencing identified new oncogenes and tumor suppressor genes in human hepatic tumors. Oncolmmunology, 2012, 1, 1612-1613.	2.1	24
206	Frequent mutations of hepatocyte nuclear factor 1 in colorectal cancer with microsatellite instability. Gastroenterology, 2003, 124, 1311-1314.	0.6	23
207	Validation of <scp>VEGFR</scp> 1 rs9582036 as predictive biomarker in metastatic clearâ€eell renal cell carcinoma patients treated with sunitinib. BJU International, 2016, 118, 890-901.	1.3	23
208	Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy. Clinical Cancer Research, 2022, 28, 540-551.	3.2	23
209	A framework for fibrolamellar carcinoma research and clinical trials. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 328-342.	8.2	23
210	Molecular Characterization of Germline NF2 Gene Rearrangements. Genomics, 2000, 65, 62-66.	1.3	22
211	Well-differentiated hepatocellular neoplasm of uncertain malignant potential. Human Pathology, 2015, 46, 634-635.	1.1	22
212	Hepatocellular Carcinomas With Mutational Activation of Beta-Catenin Require Choline and Can Be Detected by Positron Emission Tomography. Gastroenterology, 2019, 157, 807-822.	0.6	22
213	Mutation of TCF1 encoding hepatocyte nuclear factor 1α in gynecological cancer. Oncogene, 2004, 23, 7588-7592.	2.6	21
214	The pro-oncogenic effect of the lncRNA H19 in the development of chronic inflammation-mediated hepatocellular carcinoma. Oncogene, 2021, 40, 127-139.	2.6	21
215	Hepatic resection for inflammatory hepatocellular adenomas: pathological identification of micronodules expressing inflammatory proteins. Liver International, 2010, 30, 149-154.	1.9	20
216	Fighting the bushfire in HCC trials. Journal of Hepatology, 2011, 55, 276-277.	1.8	20

#	Article	IF	CITATIONS
217	Tissue biomarkers as predictors of outcome and selection of transplant candidates with hepatocellular carcinoma. Liver Transplantation, 2011, 17, S67-S71.	1.3	20
218	NRF2/KEAP1 and Wnt/β atenin in the multistep process of liver carcinogenesis in humans and rats. Hepatology, 2015, 62, 677-679.	3.6	20
219	DNA Methylation Signatures Reveal the Diversity of Processes Remodeling Hepatocellular Carcinoma Methylomes. Hepatology, 2021, 74, 816-834.	3.6	20
220	Metalloproteinase meprin $\hat{l}\pm$ regulates migration and invasion of human hepatocarcinoma cells and is a mediator of the oncoprotein Reptin. Oncotarget, 2017, 8, 7839-7851.	0.8	20
221	Preneoplastic lesions in the liver: Molecular insights and relevance for clinical practice. Liver International, 2022, 42, 492-506.	1.9	20
222	Overexpression of phosphatidylinositol 4-kinase type IIIα is associated with undifferentiated status and poor prognosis of human hepatocellular carcinoma. BMC Cancer, 2014, 14, 7.	1.1	19
223	BRAF V600E mutations in bile duct adenomas. Hepatology, 2015, 61, 403-405.	3.6	19
224	RANK/OPG ratio of expression in primary clear-cell renal cell carcinoma is associated with bone metastasis and prognosis in patients treated with anti-VEGFR-TKIs. British Journal of Cancer, 2015, 113, 1313-1322.	2.9	19
225	Plk1, upregulated by HIF-2, mediates metastasis and drug resistance of clear cell renal cell carcinoma. Communications Biology, 2021, 4, 166.	2.0	19
226	New insights in the management of Hepatocellular Adenoma. Liver International, 2020, 40, 1529-1537.	1.9	18
227	Delineation and candidate gene mutation screening of the 18q22 minimal region of deletion in head and neck squamous cell carcinoma. Oncogene, 2002, 21, 5016-5023.	2.6	17
228	Recurrent chromosomal rearrangements of <i>ROS1</i> , <i>FRK</i> and <i>IL6</i> activating JAK/STAT pathway in inflammatory hepatocellular adenomas. Gut, 2020, 69, 1667-1676.	6.1	17
229	Long-term Evolution of Hepatocellular Adenomas at MRI Follow-up. Radiology, 2020, 295, 361-372.	3.6	17
230	Deleting the β-catenin degradation domain in mouse hepatocytes drives hepatocellular carcinoma or hepatoblastoma-like tumor growth. Journal of Hepatology, 2022, 77, 424-435.	1.8	17
231	Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma. Journal of Hepatology, 2022, 77, 1038-1046.	1.8	17
232	Neurofibromatosis type 2. European Journal of Cancer, 1994, 30, 1981-1987.	1.3	16
233	MicroRNAs Targeting HIF-2α, VEGFR1 and/or VEGFR2 as Potential Predictive Biomarkers for VEGFR Tyrosine Kinase and HIF-2α Inhibitors in Metastatic Clear-Cell Renal Cell Carcinoma. Cancers, 2021, 13, 3099.	1.7	16
234	Comprehensive characterization of viral integrations and genomic aberrations in HBVâ€infected intrahepatic cholangiocarcinomas. Hepatology, 2022, 75, 997-1011.	3.6	16

#	Article	IF	CITATIONS
235	Integrative Quantitative Proteomics Unveils Proteostasis Imbalance in Human Hepatocellular Carcinoma Developed on Nonfibrotic Livers. Molecular and Cellular Proteomics, 2014, 13, 3473-3483.	2.5	15
236	Characterization of a novel PXR isoform with potential dominant-negative properties. Journal of Hepatology, 2014, 61, 609-616.	1.8	15
237	A phosphokinomeâ€based screen uncovers new drug synergies for cancer driven by liverâ€specific gain of nononcogenic receptor tyrosine kinases. Hepatology, 2017, 66, 1644-1661.	3.6	15
238	Systemic AA Amyloidosis Caused by Inflammatory Hepatocellular Adenoma. New England Journal of Medicine, 2018, 379, 1178-1180.	13.9	15
239	Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis. JHEP Reports, 2022, 4, 100390.	2.6	15
240	Rapid isolation of cosmids from defined subregions by differential Alu-PCR hybridization on chromosome 22-specific library. Genomics, 1992, 13, 395-401.	1.3	14
241	Focal βâ€eatenin mutation identified on formalinâ€fixed and paraffinâ€embedded inflammatory hepatocellular adenomas. Histopathology, 2017, 71, 989-993.	1.6	14
242	PCR-Based Genotyping Can Generate Artifacts in LOH Analyses. BioTechniques, 1999, 27, 1100-1102.	0.8	13
243	Cryptic Exons as a Source of Increased Diversity of Ewing Tumor-Associated EWS–FLI1 Chimeric Products. Genomics, 1999, 60, 371-374.	1.3	13
244	Malignant transformation of a β -catenin inflammatory adenoma due to an S45 β -catenin–activating mutation present 12 years before. Human Pathology, 2017, 62, 122-125.	1.1	13
245	Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma. Lung Cancer, 2018, 126, 15-24.	0.9	13
246	NF2 gene deletion in a family with a mild phenotype. Journal of Medical Genetics, 2000, 37, 75-77.	1.5	12
247	Adeno-associated virus type 2 as an oncogenic virus in human hepatocellular carcinoma. Molecular and Cellular Oncology, 2016, 3, e1095271.	0.3	12
248	From the Editor's desk Journal of Hepatology, 2017, 66, 1-4.	1.8	12
249	Molecular underpinnings of glandular tropism in metastatic clear cell renal cell carcinoma: therapeutic implications. Acta Oncológica, 2021, 60, 1499-1506.	0.8	12
250	Cloning of the entire FL11 gene, disrupted by the Ewing's Sarcoma translocation breakpoint on 11q24, in a yeast artificial chromosome. Cytogenetic and Genome Research, 1994, 67, 129-136.	0.6	11
251	Will the pathomolecular classification of hepatocellular adenomas improve their clinical management?. Journal of Hepatology, 2011, 55, 8-10.	1.8	11
252	Double Heterozygous Germline HNF1A Mutations in a Patient With Liver Adenomatosis. Diabetes Care, 2012, 35, e35-e35.	4.3	11

#	Article	IF	CITATIONS
253	Authors' response: virus–host interactions in HBV-related hepatocellular carcinoma: more to be revealed?. Gut, 2015, 64, 853-854.	6.1	11
254	Polymorphisms in the Von Hippel–Lindau Gene Are Associated With Overall Survival in Metastatic Clear-Cell Renal-Cell Carcinoma Patients Treated With VEGFR Tyrosine Kinase Inhibitors. Clinical Genitourinary Cancer, 2018, 16, 266-273.	0.9	11
255	Dynamics and predicted drug response of a gene network linking dedifferentiation with beta-catenin dysfunction in hepatocellular carcinoma. Journal of Hepatology, 2019, 71, 323-332.	1.8	11
256	Benign liver tumours: understanding molecular physiology to adapt clinical management. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 703-716.	8.2	11
257	Focal nodular hyperplasia with major sinusoidal dilatation: a misleading entity. BMJ Case Reports, 2010, 2010, bcr0920103311-bcr0920103311.	0.2	10
258	Synchronous hepatocellular carcinoma and Castleman's disease: The role of the interleukin-6-signaling pathway. Hepatology, 2012, 56, 392-393.	3.6	10
259	Primary Liver Carcinomas Can Originate From Different Cell Types: A New Level of Complexity in Hepatocarcinogenesis. Gastroenterology, 2013, 145, 53-55.	0.6	10
260	Hepatocellular adenoma with malignant transformation in a patient with neonatal portal vein thrombosis. Hepatology, 2016, 64, 675-677.	3.6	10
261	Genetic alterations in hepatocellular adenomas. Hepatology, 2003, 37, 480-480.	3.6	9
262	The ultimate goal of curative anti-cancer therapies: inducing an adaptive anti-tumor immune response. Frontiers in Immunology, 2011, 2, 66.	2.2	9
263	Prognostic factors of survival in <scp>HIV</scp> / <scp>HCV</scp> coâ€infected patients with hepatocellular carcinoma: The <scp>CARCINOVIC</scp> Cohort. Liver International, 2019, 39, 136-146.	1.9	9
264	MicroRNAs Possibly Involved in the Development of Bone Metastasis in Clear-Cell Renal Cell Carcinoma. Cancers, 2021, 13, 1554.	1.7	9
265	Molecular Subtypes and Gene Expression Signatures as Prognostic Features in Fully Resected Clear Cell Renal Cell Carcinoma: A Tailored Approach to Adjuvant Trials. Clinical Genitourinary Cancer, 2021, 19, e382-e394.	0.9	9
266	TGFβâ€induced FOXS1 controls epithelial–mesenchymal transition and predicts a poor prognosis in liver cancer. Hepatology Communications, 2022, 6, 1157-1171.	2.0	9
267	Dual Blockade of Epidermal Growth Factor Receptor–Induced Pathways: A New Avenue to Treat Metastatic Colorectal Cancer. Journal of Clinical Oncology, 2012, 30, 1550-1552.	0.8	8
268	AAV2 and Hepatocellular Carcinoma. Human Gene Therapy, 2016, 27, 211-213.	1.4	8
269	From the Editor's desk Journal of Hepatology, 2018, 68, 1-4.	1.8	8
270	The clinical implications of G1-G6 transcriptomic signature and 5-gene score in Korean patients with hepatocellular carcinoma. BMC Cancer, 2018, 18, 571.	1.1	8

#	Article	IF	CITATIONS
271	Elevated coffee consumption is associated with a lower risk of elevated liver fibrosis biomarkers in patients treated for chronic hepatitis B (ANRS CO22 Hepather cohort). Clinical Nutrition, 2022, 41, 610-619.	2.3	8
272	Building a bridge between obesity, inflammation and liver carcinogenesis. Journal of Hepatology, 2010, 53, 777-779.	1.8	7
273	From the Editor's Desk Journal of Hepatology, 2015, 62, 6-7.	1.8	7
274	From the Editor's desk Journal of Hepatology, 2016, 64, 1-4.	1.8	7
275	Genomics of Viral Hepatitis-Associated Liver Tumors. Journal of Clinical Medicine, 2021, 10, 1827.	1.0	7
276	In situ hybridization of PCR amplified inter-Alu sequences from a hybrid cell line. Human Genetics, 1992, 88, 541-544.	1.8	6
277	Current issues on genomic heterogeneity in hepatocellular carcinoma and its implication in clinical practice. Hepatic Oncology, 2015, 2, 291-302.	4.2	6
278	The transcriptomic G1–G6 signature of hepatocellular carcinoma in an Asian population. Medicine (United States), 2016, 95, e5263.	0.4	6
279	Human and mouse hepatocellular adenoma and carcinoma display similar tumorigenesis pathway alterations. Journal of Hepatology, 2008, 48, 884-886.	1.8	5
280	What's in a name?. Hepatology, 2009, 51, NA-NA.	3.6	5
281	From the Editor's desk Journal of Hepatology, 2017, 67, 1-4.	1.8	5
282	aCNViewer: Comprehensive genome-wide visualization of absolute copy number and copy neutral variations. PLoS ONE, 2017, 12, e0189334.	1.1	5
283	Tumor molecular characteristics in patients (pts) with international metastatic renal cell carcinoma database consortium (IMDC) good (G) and intermediate/poor (I/P) risk. Annals of Oncology, 2018, 29, viii306-viii307.	0.6	5
284	MicroRNA expression profiles in molecular subtypes of clear-cell renal cell carcinoma are associated with clinical outcome and repression of specific mRNA targets. PLoS ONE, 2020, 15, e0238809.	1.1	5
285	AICAR and compound C negatively modulate HCC-induced primary human hepatic stellate cell activation in vitro. American Journal of Physiology - Renal Physiology, 2021, 320, G543-G556.	1.6	5
286	Precise localization on chromosome 12 of the ATF-1 gene by fluorescence in situ hybridization. Human Genetics, 1994, 93, 207-8.	1.8	4
287	Single nucleotide polymorphisms in mRCC—is their time up?. Nature Reviews Urology, 2015, 12, 424-426.	1.9	4
288	Fibroblast Growth Factor Receptor-2 Polymorphism rs2981582 is Correlated With Progression-free Survival and Overall Survival in Patients With Metastatic Clear-cell Renal Cell Carcinoma Treated With Sunitinib. Clinical Genitourinary Cancer, 2019, 17, e235-e246.	0.9	4

1

#	Article	IF	CITATIONS
289	Sigma 1 Receptor is Overexpressed in Hepatocellular Adenoma: Involvement of ERα and HNF1α. Cancers, 2020, 12, 2213.	1.7	4
290	Genotype–Phenotype Relationships in Hepatocellular Carcinoma: p53 Inactivation Promotes Tumors With Stem Cell Features. Gastroenterology, 2012, 142, 1066-1069.	0.6	3
291	From the Editor's desk Journal of Hepatology, 2015, 63, 1-4.	1.8	3
292	Translating the molecular diversity of hepatocellular carcinoma into clinical practice. Molecular and Cellular Oncology, 2016, 3, e1057316.	0.3	3
293	<i>RSPO2</i> abnormal transcripts result from read-through in liver tumours with high ß-catenin activation and <i>CTNNB1</i> mutations. Gut, 2020, 69, 1152-1153.	6.1	3
294	Liver adenomatosis and NAFLD developed in the context of hereditary fructose intolerance. Liver International, 2020, 40, 3125-3126.	1.9	3
295	Severe liver fibrosis in the HCV cure era: Major effects of social vulnerability, diabetes, and unhealthy behaviors. JHEP Reports, 2022, 4, 100481.	2.6	3
296	LIM Homeobox-2 Suppresses Hallmarks of Adult and Pediatric Liver Cancers by Inactivating MAPK/ERK and Wnt/Beta-Catenin Pathways. Liver Cancer, 2022, 11, 126-140.	4.2	3
297	Genetic risk markers for hepatocellular carcinoma in patients with alcoholic liver disease. Hepatic Oncology, 2015, 2, 63-78.	4.2	2
298	From the Editor's desk Journal of Hepatology, 2016, 65, 1-4.	1.8	2
299	Cellular and Molecular Techniques. , 2018, , 88-110.		2
300	Direct, indirect and total effect of HIV coinfection on the risk of nonâ€liverâ€related cancer in hepatitis C virusâ€infected patients treated by directâ€acting antivirals: a mediation analysis. HIV Medicine, 2021, 22, 924-935.	1.0	2
301	Characterisation of 16 polymorphic markers in the NF2 gene: Application to hemizygosity detection. Human Mutation, 1999, 13, 290.	1.1	2
302	Molecular Heterogeneity Between Paired Primary and Metastatic Lesions from Clear Cell Renal Cell Carcinoma. European Urology Open Science, 2022, 40, 54-57.	0.2	2
303	R36: Sous-expression de Rnd3/RhoE dans le carcinome hépatocellulaire : implication dans l'invasion des hépatocytes tumoraux. Bulletin Du Cancer, 2010, 97, S29-S30.	0.6	1
304	Comment on: How do we interpret an elevated carbohydrate antigen 19-9 level in asymptomatic subjects?. Digestive and Liver Disease, 2010, 42, 234-235.	0.4	1
305	When activated oncogene meets immunity: A fight to prevent liver tumor initiation. Hepatology, 2012, 56, 387-389.	3.6	1

Physiopathology of Hepatocellular Carcinoma. , 2014, , 1881-1886.

#	Article	IF	CITATIONS
307	P0266 : Adeno-Associated Virus 2 (AAV2) induces recurrent insertional mutagenesis in Human Hepatocellular Carcinomas. Journal of Hepatology, 2015, 62, S406.	1.8	1
308	Direct Visualization of the Antiangiogenic Effects of Sunitinib During the Treatment of Metastatic Clear Cell Renal Cell Carcinoma. Clinical Genitourinary Cancer, 2015, 13, e407-e410.	0.9	1
309	Genotype-Phenotype Correlation of CTNNB1 Mutations Reveals Different B-Catenin Activation Levels in Hepatocellular Tumors with High Activity Associated with Malignancy. Journal of Hepatology, 2016, 64, S578.	1.8	1
310	From the Editor's desk…. Journal of Hepatology, 2016, 65, 457-461.	1.8	1
311	From the Editor's desk Journal of Hepatology, 2017, 66, 1107-1110.	1.8	1
312	Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumor classification. Journal of Hepatology, 2017, 66, S462.	1.8	1
313	From the Editor's desk Journal of Hepatology, 2017, 66, 671-674.	1.8	1
314	Reply. Hepatology, 2017, 66, 2093-2094.	3.6	1
315	From the Editor's desk Journal of Hepatology, 2018, 68, 1107-1109.	1.8	1
316	From the Editor's desk Journal of Hepatology, 2018, 69, 265-268.	1.8	1
317	PS-047-HSD17B13 loss of function variant protects from hepatocellular carcinoma developed on alcohol related liver disease. Journal of Hepatology, 2019, 70, e29-e30.	1.8	1
318	Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation. Clinical Genitourinary Cancer, 2019, 17, e909-e912.	0.9	1
319	Journal of Hepatology: The Home of Liver Research, 2015–2019. Journal of Hepatology, 2019, 71, 1065-1069.	1.8	1
320	686P Angiogenesis related blood biomarkers of response to checkpoint inhibitors (IO) and VEGFR-TKI in metastatic renal cell carcinoma (mRCC): Results from the BIONIKK prospective trial. Annals of Oncology, 2021, 32, S704.	0.6	1
321	Benign Liver Tumors. Molecular Pathology Library, 2011, , 769-775.	0.1	1
322	Prognostic Significance of SALL4 Expression Levels in Paediatric Acute Myeloid Leukaemia (AML) Blood, 2008, 112, 2243-2243.	0.6	1
323	Genetic Alterations in the Chromosome 22q12 Region Associated with Development of Neuroectodermal Tumors. Cold Spring Harbor Symposia on Quantitative Biology, 1994, 59, 555-564.	2.0	1
324	Abstract 112: Genetic alterations in molecular tumor subgroups of malignant pleural mesothelioma. ,		1

2016, , .

0

#	Article	IF	CITATIONS
325	Re: A Novel Epigenetic Phenotype Associated With the Most Aggressive Pathway of Bladder Tumor Progression. Journal of Urology, 2011, 186, 456-456.	0.2	0
326	Familial liver adenomatosis. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	0
327	From the Editor's desk…. Journal of Hepatology, 2015, 63, 775-777.	1.8	0
328	From the Editor's desk Journal of Hepatology, 2015, 63, 1057-1061.	1.8	0
329	From the Editor's desk Journal of Hepatology, 2015, 63, 1299-1302.	1.8	Ο
330	From the Editor's desk…. Journal of Hepatology, 2015, 62, 991-994.	1.8	0
331	P0265 : IGF2 is an oncogenic driver in HCC and emerges as a potential target for therapies. Journal of Hepatology, 2015, 62, S405-S406.	1.8	Ο
332	From the Editor's desk Journal of Hepatology, 2015, 62, 1221-1224.	1.8	0
333	P0480 : Role of the immune microenvironment during hepatocellular carcinoma. Journal of Hepatology, 2015, 62, S494.	1.8	Ο
334	From the Editor's desk Journal of Hepatology, 2015, 63, 537-539.	1.8	0
335	From the Editor's desk Journal of Hepatology, 2016, 65, 1073-1076.	1.8	Ο
336	Reply. Hepatology, 2016, 63, 342-342.	3.6	0
337	From the Editor's desk Journal of Hepatology, 2016, 64, 1199-1202.	1.8	Ο
338	From the Editor's desk Journal of Hepatology, 2016, 64, 759-762.	1.8	0
339	From the Editor's desk Journal of Hepatology, 2016, 65, 233-236.	1.8	Ο
340	From the Editor's desk Journal of Hepatology, 2016, 65, 657-660.	1.8	0
341	From the Editor's desk Journal of Hepatology, 2016, 65, 869-872.	1.8	0
0.46			

Genomic Signatures of Risk Factors and Molecular Identification of HCC Subtypes. , 2016, , 113-119.

#	Article	IF	CITATIONS
343	From the Editor's desk Journal of Hepatology, 2016, 64, 991-995.	1.8	Ο
344	From the Editor's desk Journal of Hepatology, 2016, 64, 253-256.	1.8	0
345	From the Editor's desk Journal of Hepatology, 2016, 64, 527-531.	1.8	0
346	From the Editor's desk Journal of Hepatology, 2017, 66, 263-266.	1.8	0
347	From the Editor's desk Journal of Hepatology, 2017, 66, 469-472.	1.8	0
348	From the Editor's desk Journal of Hepatology, 2017, 67, 659-662.	1.8	0
349	From the Editor's desk Journal of Hepatology, 2017, 67, 889-892.	1.8	0
350	From the Editor's desk Journal of Hepatology, 2017, 67, 437-440.	1.8	0
351	From the Editor's desk Journal of Hepatology, 2017, 67, 207-210.	1.8	0
352	From the Editor's desk Journal of Hepatology, 2017, 67, 1125-1128.	1.8	0
353	From the Editor's desk Journal of Hepatology, 2018, 68, 377-379.	1.8	0
354	From the Editor's desk Journal of Hepatology, 2018, 68, 631-634.	1.8	0
355	From the Editor's desk.…. Journal of Hepatology, 2018, 69, 1209-1212.	1.8	Ο
356	From the Editor's Desk…. Journal of Hepatology, 2018, 69, 759-761.	1.8	0
357	From the Editor's desk Journal of Hepatology, 2018, 69, 993-995.	1.8	Ο
358	Sigma 1 receptor: a potential actor in Hepato-Cellular Adenomas. Journal of Hepatology, 2018, 68, S48.	1.8	0
359	From the Editor's desk Journal of Hepatology, 2018, 68, 869-872.	1.8	0
360	AAV2 viral infection in liver and tumor development. Journal of Hepatology, 2018, 68, S664-S665.	1.8	0

#	Article	IF	CITATIONS
361	Corrigendum to "From the Editor's Desk August 2018―[J Hepatol 69 (2018) 265–268]. Journal of Hepatology, 2018, 69, 987.	1.8	0
362	From the Editor's desk Journal of Hepatology, 2018, 69, 559-561.	1.8	0
363	From the Editor's desk…. Journal of Hepatology, 2019, 71, 231-234.	1.8	Ο
364	Advanced clear-cell renal cell carcinoma (accRCC): Association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome. Annals of Oncology, 2019, 30, v394-v395.	0.6	0
365	From the Editor's Desk…. Journal of Hepatology, 2019, 71, 853-855.	1.8	0
366	THU-456-Polyploidy spectrum: a new marker of molecular HCC tumour classification. Journal of Hepatology, 2019, 70, e360.	1.8	0
367	THU-374-The INCRNA H19-dervied MIR-675 promotes liver necroptosis by targeting fadd. Journal of Hepatology, 2019, 70, e318.	1.8	0
368	THU-445-Beta-catenin signaling controls NKG2D ligands expression in liver tumorigenesis. Journal of Hepatology, 2019, 70, e354-e355.	1.8	0
369	FRI-465-The INCRNA H19 is an oncogenic driver of HCC in chronic inflammation-mediated mouse model. Journal of Hepatology, 2019, 70, e601-e602.	1.8	Ο
370	THU-452-TFOX, a novel TGF-beta target gene, switches TGF-beta activity toward EMT during tumor progression of human hepatocellular carcinoma. Journal of Hepatology, 2019, 70, e357-e358.	1.8	0
371	From the Editor's Desk…. Journal of Hepatology, 2019, 71, 641-644.	1.8	0
372	From the Editor's desk…. Journal of Hepatology, 2019, 70, 1039-1042.	1.8	0
373	JHEP Reports: A new EASL open access journal. JHEP Reports, 2019, 1, 1.	2.6	Ο
374	From the Editor's desk…. Journal of Hepatology, 2019, 71, 1-4.	1.8	0
375	From the Editor's desk…. Journal of Hepatology, 2019, 70, 583-586.	1.8	Ο
376	From the Editor's desk…. Journal of Hepatology, 2019, 70, 819-821.	1.8	0
377	From the Editor's desk Journal of Hepatology, 2019, 70, 335-338.	1.8	0
378	From the Editor's Desk…. Journal of Hepatology, 2019, 71, 1061-1064.	1.8	0

#	Article	IF	CITATIONS
379	Validation of the Correlation Between Single Nucleotide Polymorphism rs307826 in VEGFR3 and Outcome in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Sunitinib. Kidney Cancer, 2020, 4, 139-149.	0.2	0
380	Gene Mutations and Transcriptomic Profiles Associated to Specific Subtypes of Hepatocellular Tumors. , 2010, , 259-275.		0
381	Liver adenoma. Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2011, , .	0.1	Ο
382	Abstract 5121: Acquired inactivating ARID2 mutations in lung non small cell carcinoma. , 2012, , .		0
383	Abstract 1609: Proline-directed kinase signaling in human hepatocellular carcinomas developed on non-fibrotic liver. , 2014, , .		Ο
384	Use of Molecular Biology for Identifying Benign Hepatocellular Tumors Leads to More Personalized Medicine. MD Conference Express, 2014, 14, 6-8.	0.0	0
385	Molecular subtypes and prognosis in RCC. Aging, 2015, 7, 219-220.	1.4	Ο
386	Abstract 2973: Exome sequencing of 243 liver tumors identifies new mutational signatures and potential therapeutic targets. , 2015, , .		0
387	Abstract 919: Adeno-associated virus 2 (AAV2) induces recurrent insertional mutagenesis in human hepatocellular carcinomas. , 2015, , .		0
388	Abstract IA20: Cancer subtypes and their immune microenvironments. , 2016, , .		0
389	Abstract 3666: Co-occurring mutations of tumors suppressor genes, NF2 and LATS2, in malignant pleural mesothelioma. , 2016, , .		Ο
390	Abstract 1257: A MYC-Aurka protein complex represents an actionable target in p53 altered liver cancer. , 2016, , .		0
391	Abstract IA10: Tumor microenvironments: Prognostic and theranostic impacts. , 2016, , .		Ο
392	Metastatic clear cell renal cell carcinoma: Proangiogenic gene expression and outcome on sunitinib Journal of Clinical Oncology, 2017, 35, e16085-e16085.	0.8	0
393	Re: Molecular Subtypes of Clear-Cell Renal Cell Carcinoma are Prognostic for Outcome after Complete Metastasectomy. Journal of Urology, 2019, 201, 664-665.	0.2	0
394	Structure, Dynamics, and Impact of Replication Stress–Induced Structural Variants in Hepatocellular Carcinoma. Cancer Research, 2022, 82, 1470-1481.	0.4	0